Abstract: Several embodiments of the present invention are generally directed to medical visualization systems that comprise combinations of disposable and reusable components, such as catheters, functional handles, hubs, optical devices, etc. Other embodiments of the present invention are generally directed to features and aspects of an in-vivo visualization system that comprises an endoscope having a working channel through which a catheter having viewing capabilities is routed. the catheter may obtain viewing capabilities by being constructed as a vision catheter or by having a fiberscope or other viewing device selectively routed through one of its channels. The catheter is preferably of the steerable type so that the distal end of the catheter may be steered from its proximal end as it is advanced with the body. A suitable use for the in-vivo visualization system includes but is not limited to diagnosis and/or treatment of the duodenum, and particularly the biliary tree.

Abstract: Provided in some embodiments are methods of treating or preventing Raynaud's, comprising prescribing and/or administering to an individual in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Abstract: The present invention relates to, inter alia, methods of treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) for scleroderma in an individual in need thereof.

Abstract: A method is provided that includes monitoring a process of manufacturing a composite structure that includes introducing a matrix material to a reinforcement material, applying the reinforcement material into a mold cavity or onto a mold surface with a first machine tool, subjecting the matrix material to a melding event with a second machine tool, and inspecting the composite structure. Data including at least one of first measurement data, error data or second measurement data is determined, and an analysis of the data is performed to summarize the data and thereby produce feedback data including a summary of the data. At least one of the process, the first machine tool or the second machine tool is adjusted based on feedback including the summary, and for manufacture of a next composite structure.

Abstract: A method is provided that includes monitoring a process of manufacturing a composite structure that includes introducing a matrix material to a reinforcement material, applying the reinforcement material into a mold cavity or onto a mold surface with a first machine tool, subjecting the matrix material to a melding event with a second machine tool, and inspecting the composite structure. Data including at least one of first measurement data, error data or second measurement data is determined, and an analysis of the data is performed to summarize the data and thereby produce feedback data including a summary of the data. At least one of the process, the first machine tool or the second machine tool is adjusted based on feedback including the summary, and for manufacture of a next composite structure.

Abstract: Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

Abstract: Provided in some embodiments are methods of treating or preventing Raynaud's, comprising prescribing and/or administering to an individual in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Abstract: The present invention relates to 4-[6-(6-Methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester (Compound 1), pharmaceutically acceptable salts, solvates, and hydrates thereof that modulate the activity of the GPR119 receptor. Compound 1 and pharmaceutical compositions thereof are directed to methods useful in the treatment of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and conditions related thereto.

Abstract: The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and/or frequency of ralinepag and/or riociguat, reduced doses and/or frequency of ralinepag and/or treprostinil, and reduced doses and/or frequency of ralinepag and/or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and/or iloprost monotherapies.

Abstract: A system and process for administration of bundled health care pricing, packaged health care, case rates, or episodes of care. The system may include software to automate administrative functions. The disclosure relates to processes including the steps of distributing payments, calculating savings, and processing claims associated with bundled health care pricing.

Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In some embodiments, the GPCR is mammalian, preferably human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gq. In some embodiments, the GPCR increases the intracellular level of inositol 1,4,5-triphosphate (IP3). In some embodiments, a modulator of the GPCR is a modulator of cardiomyocyte hypertrophy. The present invention further relates to methods of using a modulator of the GPCR. Preferred modulators are inverse agonists and antagonists.

Abstract: A reporting system for displaying to a user a plurality of key financial performance metrics about a practice, said reporting system comprising one or more user computers, each of said user computers having a practice digital dashboard for displaying said plurality of key financial performance metrics, wherein said practice digital dashboard includes one or more selectable data analysis interfaces to present said plurality of key financial performance metrics in a grid of one or more tables, graphs, or charts; one or more data servers in communication with each of the user computers, each data server comprising a set of billing and collection information for said practice and one or more functions for computing said plurality of key financial performance metrics from said set of billing and collection information for said practice; and a network allowing communication between said one or more user computers and said one or more data servers.

Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia/reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

Abstract: A method and apparatus for picking and collecting fruit from fruit trees comprising a fruit picking assembly including a water cannon to selectively impact fruit to be picked with a water slug to detach the fruit from the fruit tree and a fruit collecting assembly disposed beneath the fruit picking assembly to catch the fruit detatched from the fruit tree.

Abstract: A method and apparatus for picking and collecting fruit from fruit trees comprising a fruit picking assembly including a water cannon to selectively impact fruit to be picked with a water slug to detach the fruit from the fruit tree and a fruit collecting assembly disposed beneath the fruit picking assembly to catch the fruit detatched from the fruit tree.

Abstract: The invention relates to a support stand including at least three outwardly extending and diverging legs. A distal end of each of the legs defines a notional perimeter having at least three corners. Each of the legs extends outwardly to a respective one of the corners. A distal support column is located at respective distal ends of the legs and provides an area of increased rigidity. The support column defines a respective corner of the notional perimeter.

Abstract: An exterior gas-fired water heater enclosure, comprising a base, sidewalls mounted on the base and defining an interior space for receiving a gas-fired water heater, a top positioned on the top of the sidewalls, a flue positioned in the top and communicating with the interior of the enclosure for discharging heated combustion air from the enclosure, vent means positioned adjacent the bottom of the sidewalls for permitting air flow into the enclosure from a point closely proximate a gas burner positioned in the bottom of the water heater, and baffle means positioned over the vent means for directing all of the air flow through the vent downwardly to a position below the gas burner of the water heater.

Abstract: A pocket watch display kit comprising a hollow box like housing forming an open ended chamber, a lateral support shelf affixed with the housing dividing the open ended chamber and forming an upper chamber and a lower chamber, the lateral support shelf adapted to support a pocket watch, a semi-oblongitudinal notch in the free edge of the upper lateral portion of the housing, the crown of the pocket accommodated between the internal edges of the notch, a pendulum pivotally disposed within the lower chamber, a first door element hingedly affixed over the upper chamber, the door element having a first transparent window therein permitting display of the face of the pocket watch, a lower panel element fixedly secured to the housing adjacent the lower lateral portion thereof, and a second door element hingedly affixed by second hinge means over the opening in the lower chamber above the lower panel, the second door element having a second transparent window therein permitting the viewing of the pendulum element and